22 Dec 2017 12:10
Creo Medical Group plc (the "Company")
Director/PDMR Dealing
The Company announces that it has received notice of exercise of options ("Options") under the Company's EMI Share Option Scheme from Steven Morris, Chief Operating Officer, a PDMR, to subscribe for 115,000 Ordinary Shares of £0.001 each in the Company (the "New Ordinary Shares"). The exercise price of the Options is 15.56 pence each.
Following the exercise of these Options Mr Morris will hold 115,000 Ordinary Shares in the Company representing approximately 0.1423 per cent. of the Company's issued share capital.
Application has been made to AIM for the admission of the New Ordinary Shares to trading on AIM ("Admission") and Admission is expected to occur on or around 3 January 2018.
Following the issue of the New Ordinary Shares the Company's total issued share capital will consist of 80,826,745 Ordinary Shares. The Company does not hold any Ordinary Shares in Treasury. Therefore, following the issue of the New Ordinary Shares the total number of voting rights in the Company is 80,826,745. This figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||
a)
| Name
| Steven Morris | ||||
2
| Reason for the notification
| |||||
a)
| Position/status
| Chief Operating Officer | ||||
b)
| Initial notification /Amendment
| Initial | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||
a)
| Name
| Creo Medical Group plc | ||||
b)
| LEI
| 213800H188ZDCWWXFA21 | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||
a)
| Description of the financial instrument, type of instrument
Identification code
|
Ordinary shares of £0.001 each
GB00BZ1BLL44 | ||||
b)
| Nature of the transaction
| Exercise of shares options | ||||
c)
| Price(s) and volume(s)
|
| ||||
d)
| Aggregated information
- Aggregated volume
- Price
|
Weighted average price of 15.56 per share
| ||||
e)
| Date of the transaction
| 22 December 2017 | ||||
f)
| Place of the transaction
| Off Market | ||||
Contacts
Creo Medical: | Cenkos: | FTI Consulting: |
Richard Rees +44 (0)129 160 6005 richard.rees@creomedical.com | Camilla Hume/Mark Connelly (NOMAD) Michael Johnson / Russell Kerr (Sales) +44 (0)207 397 8900 | Brett Pollard / Mo Noonan +44 (0)203 727 1000 creo@fticonsulting.com |
About Creo Medical
Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and radiowave energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides physicians with flexible, accurate and controlled surgical solutions.
The Company's strategy is to bring the CROMA surgical system to market through a suite of medical instruments which the Company has designed, initially for GI therapeutic endoscopy, an area with high unmet needs. The CROMA system will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing safer, less-invasive and more cost-efficient option of treatment.
For more information about Creo Medical please see our website, www.creomedical.com.
Creo Medical (CREO)